Bensler LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Bensler LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 5.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,985 shares of the company’s stock after purchasing an additional 109 shares during the quarter. Bensler LLC’s holdings in Johnson & Johnson were worth $287,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Jeppson Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 2.0% in the fourth quarter. Jeppson Wealth Management LLC now owns 14,341 shares of the company’s stock valued at $2,074,000 after buying an additional 286 shares in the last quarter. MBE Wealth Management LLC boosted its position in shares of Johnson & Johnson by 6.3% during the 4th quarter. MBE Wealth Management LLC now owns 1,653 shares of the company’s stock worth $239,000 after purchasing an additional 98 shares in the last quarter. KFA Private Wealth Group LLC increased its holdings in shares of Johnson & Johnson by 30.6% in the 4th quarter. KFA Private Wealth Group LLC now owns 3,266 shares of the company’s stock valued at $472,000 after purchasing an additional 765 shares in the last quarter. VCI Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 32.9% in the fourth quarter. VCI Wealth Management LLC now owns 19,399 shares of the company’s stock valued at $2,805,000 after purchasing an additional 4,805 shares during the period. Finally, Curbstone Financial Management Corp boosted its holdings in Johnson & Johnson by 1.1% during the fourth quarter. Curbstone Financial Management Corp now owns 26,732 shares of the company’s stock worth $3,866,000 after buying an additional 280 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on JNJ. Citigroup reduced their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Leerink Partners decreased their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Barclays raised their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $170.44.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $152.09 on Friday. The business’s 50-day moving average price is $147.67 and its 200 day moving average price is $156.07. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a market capitalization of $366.17 billion, a PE ratio of 22.87, a price-to-earnings-growth ratio of 2.43 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the company earned $2.29 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.26%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.